©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplantation. Sep 10, 2018; 8(5): 150-155
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.150
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.150
Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
Junji Uchida, Tomoaki Iwai, Tatsuya Nakatani, Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Author contributions: Uchida J, Iwai T and Nakatani T contributed equally to this work, generated the tables and wrote the manuscript.
Conflict-of-interest statement: We have no personal or financial interests to declare, and we have no financial support from an industry source for the current manuscript.
Correspondence to: Junji Uchida, MD, PhD, Associate Professor, Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3, Abeno-ku, Asahi-machi, Osaka 545-8585, Japan. m9492120@msic.med.osaka-cu.ac.jp
Telephone: +81-6-66453857 Fax: +81-6-66474426
Received: May 21, 2018
Peer-review started: May 21, 2018
First decision: June 6, 2018
Revised: June 23, 2018
Accepted: June 27, 2018
Article in press: June 28, 2018
Published online: September 10, 2018
Processing time: 109 Days and 4.2 Hours
Peer-review started: May 21, 2018
First decision: June 6, 2018
Revised: June 23, 2018
Accepted: June 27, 2018
Article in press: June 28, 2018
Published online: September 10, 2018
Processing time: 109 Days and 4.2 Hours
Core Tip
Core tip: Current immunosuppressive protocols consisting of calcineurin inhibitors (CNIs) and mycophenolate mofetil have improved short-term graft survival. However, improvements in long-term graft survival are restricted by nephrotoxicity associated with CNI. Everolimus is an exceedingly useful immunosuppressant for kidney transplant recipients when administered in combination with low-dose CNIs or with elimination of CNIs. Here, we summarize the current knowledge about the introduction of everolimus with CNI elimination or minimization in kidney transplant recipients at late posttransplant stage.